Patricia N Sidharta
Overview
Explore the profile of Patricia N Sidharta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huynh C, Dingemanse J, Zu Schwabedissen H, Fonseca M, Sidharta P
Clin Transl Sci
. 2024 Jul;
17(7):e13883.
PMID: 39010703
Cytochrome P450 (CYP) 3A4 is an enzyme involved in the metabolism of many drugs that are currently on the market and is therefore a key player in drug-drug interactions (DDIs)....
2.
Brussee J, Sidharta P, Dingemanse J, Krause A
J Pharmacokinet Pharmacodyn
. 2024 Feb;
51(3):243-252.
PMID: 38332190
Aprocitentan is a novel, potent, dual endothelin receptor antagonist that recently demonstrated efficacy in the treatment of difficult-to-treat (resistant) hypertension. The aim of this study was to develop a population...
3.
Fontes M, Dingemanse J, Halabi A, Tomaszewska-Kiecana M, Sidharta P
Sci Rep
. 2022 Nov;
12(1):19067.
PMID: 36352054
The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerability of the dual endothelin receptor antagonist aprocitentan was clinically investigated as 25% of aprocitentan is cleared through...
4.
Huynh C, Seeland S, Segrestaa J, Gnerre C, Hogeback J, Zu Schwabedissen H, et al.
Front Pharmacol
. 2022 Apr;
13:812065.
PMID: 35431953
ACT-1004-1239 is a potent, selective, first-in-class CXCR7 antagonist, which shows a favorable preclinical and clinical profile. Here we report the metabolites and the metabolic pathways of ACT-1004-1239 identified using results...
5.
Huynh C, Brussee J, Pouzol L, Fonseca M, Zu Schwabedissen H, Dingemanse J, et al.
Biomed Pharmacother
. 2021 Nov;
144:112363.
PMID: 34794236
Antagonism of the chemokine receptor CXCR7 has shown promising effects in diverse disease areas through modulation of its ligands, CXCL11 and CXCL12. Preclinical data of the first-in-class CXCR7 antagonist, ACT-1004-1239,...
6.
Gehin M, Wierdak J, Sabattini G, Sidharta P, Dingemanse J
Br J Clin Pharmacol
. 2021 Aug;
88(2):810-819.
PMID: 34371524
Aims: Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia. The solubility of daridorexant is pH-dependent and daridorexant has been shown to be a sensitive CYP3A4...
7.
Sidharta P, Fischer H, Dingemanse J
Curr Drug Metab
. 2021 Feb;
22(5):399-410.
PMID: 33563190
Background: Aprocitentan is an orally active, dual endothelin receptor antagonist that may offer a new therapeutic option for the treatment of difficult-to-control hypertension. Objective: To investigate safety, tolerability, mass balance,...
8.
Melchior M, Dingemanse J, Alatrach A, Feldkamp T, Sidharta P, Gehin M
J Clin Pharmacol
. 2020 Dec;
61(7):932-938.
PMID: 33368330
Sinbaglustat (ACT-519276), a brain-penetrating inhibitor of glucosylceramide synthase and nonlysosomal glucosylceramidase, is developed as a new therapy for lysosomal storage disorders. In the first-in-human study, sinbaglustat was primarily excreted unchanged...
9.
Gehin M, Melchior M, Welford R, Sidharta P, Dingemanse J
Clin Transl Sci
. 2020 Nov;
14(2):558-567.
PMID: 33142037
In this first-in-human study, the tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of sinbaglustat, a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase...
10.
Mueller M, Sidharta P, Voors-Pette C, Darpo B, Xue H, Dingemanse J
Orphanet J Rare Dis
. 2020 Oct;
15(1):303.
PMID: 33109218
Background: Fabry disease is a rare inherited glycosphingolipid storage disorder caused by deleterious mutations in the GLA gene coding for the lysosomal enzyme α-galactosidase A. The glucosylceramide synthase inhibitor lucerastat...